搜索优化
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按相关度排序
按时间排序
FierceBiotech
4 天
Roche culls cough candidate, pivots KRAS program after revaluing entire pipeline
Roche’s chronic cough program has sputtered to a halt. The drugmaker, which axed the program after the drug candidate ...
GEN
2 天
Roche, Dyno Launch $1B+ AAV Gene Therapy Vector Collaboration
Roche will use Dyno’s technology, through which Dyno applies AI and high-throughput in vivo data collection to engineering ...
BioSpace
3 天
Roche Inks Potential $1B Gene Therapy Deal With Dyno, Eyes Neurological Diseases
With an upfront payment of $50 million from Roche, the partnership will leverage Dyno Therapeutics’ in vivo gene therapy ...
生物谷
13 天
罗氏公司发布最新临床数据,单抗药物可持续减缓帕金森病进展
Prasinezumab是一种人源化单克隆抗体,是首个被设计用来靶向α-突触核蛋白(α-Syn)从而促进其降解的实验性单克隆抗体,有望通过抑制致病性的α-突触核蛋白在细胞间的扩散来保护神经元、减缓帕金森病进展。
BioSpace
4 天
Roche Beats Q3 Sales Estimates as CEO Voices Opposition to Novo Holdings’ Catalent Buyout
Jefferies analyst Peter Welford noted that Roche’s pharma group came just slightly ahead of consensus expectations, driven by ...
precisionmedicineonline
3 天
Roche Sees Strong Demand for Elevidys Gene Therapy Amid Steady Q3 Pharmaceutical Revenue Growth
About 500 children worldwide have received the gene therapy, including some families traveling abroad to gain access to it.
4 天
Roche CEO Is Optimistic on Coming Alzheimer’s Trial Results
Roche Holding AG said its third-quarter sales rose thanks to eye drug Vabysmo as well as medicines for cancer, hemophilia and ...
Swissinfo
7 天
Roche’s big bet on big diseases
Swiss pharma giant Roche is refocusing its R&D investment on diseases like obesity that weigh heavily on healthcare budgets.
sharewise
5 天
Can Roche Challenge Lilly and Novo in the Weight Loss Market?
Over the last couple of years, one of the biggest stories in the stock market has been around pharmaceutical companies that ...
Real Simple on MSN
1 天
Dermatologists Have Spoken: These Are the 10 Products You Need to Winterize Your Skincare ...
And while we often feel the dryness on our face first, our hands and legs experience it, too, shares Dr. Azadeh Shirazi, ...
precisionmedicineonline
8 天
FDA Approves Astellas' Vyloy, Chemo in First-Line CLDN18.2-Positive Gastric Cancer With ...
Vyloy is the first CLDN18.2-targeted treatment to reach the US market alongside Roche's Ventana CLDN18 RxDx Assay for identifying eligible patients.
10 天
Poseida股价保持稳定,分析师重申买入评级,关注多发性骨髓瘤研究
周四,H.C. Wainwright重申了对Poseida Therapeutics, Inc (NASDAQ:PSTX)的买入评级,目标股价为$20.00。这一确认是在该公司于2024年9月27日在国际骨髓瘤协会年会上发布了一项正在进行的研究的积极数据之后做出的。这项与Roche合作进行的研究正在评估P-BCMA-ALLO1用于治疗复发和难治性多发性骨髓瘤(r/r MM)。 研究中重点关注的数据 ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈